약물감시(PharmaCovigilances) 시장 규모, 점유율, 성장 분석 : 수명주기별, 유형별, 배포별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
PharmaCovigilances Market Size, Share, and Growth Analysis, By Life Cycle (Pre-clinical, Phase I), By Type (Spontaneous Reporting, Intensified ADR Reporting), By Deployment, By End User, By Region - Industry Forecast 2025-2032
상품코드:1673649
리서치사:SkyQuest
발행일:2025년 03월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
약물감시(PharmaCovigilances) 시장 규모는 2023년에 75억 달러로 평가되며, 2024년 80억 1,000만 달러에서 2032년에는 135억 6,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 6.8%로 성장할 전망입니다.
세계 약물감시 시장은 환자 안전에 대한 중요성 증가, 규제 당국의 엄격한 요구, 제약 부문의 성장에 힘입어 강력한 성장세를 보이고 있습니다. 주요 촉진요인으로는 새로운 치료법 개발이 복잡해지고 의약품 소비량이 증가함에 따라 의약품 안전성 모니터링의 필요성이 증가하고 있다는 점을 들 수 있습니다. 규제 당국이 보다 엄격한 가이드라인을 시행함에 따라 제약사들은 약물감시 업무를 강화할 수밖에 없었고, 이는 시장 확대를 더욱 촉진하고 있습니다. 또한 만성질환의 급증은 약물 부작용을 식별하고 완화하여 환자 안전을 향상시키고 의료 비용을 절감하는 데 있으며, 약물감시의 중요한 역할을 강조하고 있습니다. 의료 프로바이더와 규제기관이 효과적인 약물감시 시스템을 우선시하는 노력을 결합하여 의료 성과와 환자 복지를 크게 개선하는 것을 목표로 하고 있습니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
규제 상황
사례 연구
기술의 진보
무역 분석
약물감시 시장 규모 : 수명주기별 & CAGR(2025-2032)
시장 개요
전임상
단계 I
단계 II
단계 III
단계 IV
약물감시 시장 규모 : 유형별 & CAGR(2025-2032)
시장 개요
자발적 보고
ADR 보고의 강화
타깃 자발적 보고
코호트 이벤트 모니터링
EHR 마이닝
약물감시 시장 규모 : 배포별 & CAGR(2025-2032)
시장 개요
사내
계약 아웃소싱
약물감시 시장 규모 : 최종사용자별 & CAGR(2025-2032)
시장 개요
계약 조사기관(CRO)
제약·바이오테크놀러지 기업
기타
약물감시 시장 규모 : 지역별 & CAGR(2025-2032)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
기업의 상세
제품 포트폴리오 분석
기업의 부문별 점유율 분석
매출의 전년대비 비교(2022-2024)
주요 기업 개요
Accenture(Ireland)
IQVIA Inc.(United States)
Cognizant(United States)
IBM Corporation(United States)
Capgemini(France)
ITClinical(Portugal)
ICON plc(Ireland)
TAKE Solutions Limited(India)
Parexel International Corporation(United States)
Wipro(India)
United BioSource LLC(United States)
BioClinica Inc.(Clario)(United States)
ClinChoice(formerly FMD K&L)(United States)
Linical Americas(United States)
Science 37 Holdings, Inc.(United States)
LEO Pharma(Denmark)
argenx(Belgium)
Purisys(United States)
결론과 제안
KSA
영문 목차
영문목차
PharmaCovigilances Market size was valued at USD 7.5 billion in 2023 and is poised to grow from USD 8.01 billion in 2024 to USD 13.56 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).
The global pharmacovigilance market is witnessing robust growth, propelled by an increasing emphasis on patient safety, stringent regulatory demands, and the expanding pharmaceutical sector. Key drivers include the heightened necessity for drug safety monitoring amid the complexity of new therapeutic developments and rising drug consumption. As regulatory agencies enforce more rigorous guidelines, pharmaceutical companies are compelled to enhance their pharmacovigilance practices, further stimulating market expansion. Additionally, the surge in chronic disease prevalence underscores the critical role of pharmacovigilance in identifying and mitigating adverse drug reactions, thereby enhancing patient safety and reducing healthcare costs. The combined efforts of healthcare providers and regulatory bodies to prioritize effective pharmacovigilance systems aim to improve healthcare outcomes and patient welfare significantly.
Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmacovigilances market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Pharmacovigilances Market Segments Analysis
Global PharmaCovigilances Market is segmented by Life Cycle, Type, Deployment, End User and region. Based on Life Cycle, the market is segmented into Pre-clinical, Phase I, Phase II, Phase III and Phase IV. Based on Type, the market is segmented into Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining. Based on Deployment, the market is segmented into In-house and Contract Outsourcing. Based on End User, the market is segmented into Contract Research Organizations (CROs), Pharmaceutical & Biotechnology Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Pharmacovigilances Market
The global pharmacovigilance market is experiencing significant growth due to the rising prevalence of adverse drug reactions (ADRs) worldwide. As pharmaceutical product usage continues to grow, so does the likelihood of individuals facing unexpected side effects. Pharmacovigilance is essential for monitoring and reporting these ADRs, enabling early detection, risk assessment, and the implementation of necessary actions to protect patient health. The increasing need for effective pharmacovigilance services and solutions is driven by the urgency to manage the escalating rates of ADRs, thereby contributing to the market's expansion and highlighting its vital importance in ensuring drug safety.
Restraints in the Pharmacovigilances Market
A notable challenge within the global pharmacovigilance market is the limited awareness and insufficient infrastructure present in developing regions. These areas struggle to create and implement comprehensive pharmacovigilance systems. The lack of understanding about the importance of pharmacovigilance, coupled with weak regulatory frameworks and resource limitations, hampers the integration of effective practices. Additionally, the presence of inadequate infrastructure, a shortage of trained personnel, and poor data management systems contribute to obstacles for the advancement of the pharmacovigilance market in these regions, ultimately impeding its growth and effectiveness in ensuring drug safety.
Market Trends of the Pharmacovigilances Market
The pharmacovigilance market is witnessing robust growth driven by the escalating consumption and development of pharmaceuticals, significantly increasing the necessity for monitoring drug safety. With high-profile recalls like Aurobindo Pharma's 2022 Quinapril withdrawal, the industry is under pressure to manage adverse drug reactions effectively. This has led regulatory authorities to demand more extensive medical information, fueling market expansion. Additionally, partnerships such as IQVIA's collaboration with NRx Pharmaceuticals signal a strategic shift towards comprehensive pharmacovigilance services, enhancing compliance and patient safety. As awareness of drug-related risks rises, the pharmacovigilance sector is poised for sustained growth, underscoring its critical role in healthcare.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement
Trade Analysis
Global PharmaCovigilances Market Size by Life Cycle & CAGR (2025-2032)
Market Overview
Pre-clinical
Phase I
Phase II
Phase III
Phase IV
Global PharmaCovigilances Market Size by Type & CAGR (2025-2032)
Market Overview
Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining
Global PharmaCovigilances Market Size by Deployment & CAGR (2025-2032)
Market Overview
In-house
Contract Outsourcing
Global PharmaCovigilances Market Size by End User & CAGR (2025-2032)
Market Overview
Contract Research Organizations (CROs)
Pharmaceutical & Biotechnology Companies
Others
Global PharmaCovigilances Market Size & CAGR (2025-2032)
North America (Life Cycle, Type, Deployment, End User)
US
Canada
Europe (Life Cycle, Type, Deployment, End User)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Life Cycle, Type, Deployment, End User)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Life Cycle, Type, Deployment, End User)
Brazil
Rest of Latin America
Middle East & Africa (Life Cycle, Type, Deployment, End User)
